drugset
drugset / Trial / NCT07133425

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

NCT07133425 ↗

Phase 2 Recruiting 29 enrolled M.D. Anderson Cancer Center Sanofi · collab
NaSingle-groupOpen-labelTreatment

Summary

To learn if SAR445877 can help to control locally advanced or metastatic NSCLC in patients who have previously received ICI therapy.

Timeline

Start
2025-11-06
Primary completion
2028-02-01
Completion
2030-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SAR445877 Unknown — Intravenous

Indications

non-small cell lung carcinoma refractory malignant neoplasm